On April 12, Novogene Co.Ltd(688315) handed over its first annual “report card” on the occasion of the first anniversary of landing on the science and innovation board. According to the financial report, in 2021, Novogene Co.Ltd(688315) achieved an operating revenue of 1.866 billion yuan, a year-on-year increase of 25.26%; The net profit attributable to the shareholders of the listed company was 225 million yuan, a year-on-year increase of 515.74%; The gross profit margin of main business increased from 35.11% in 2020 to 42.88%.
Novogene Co.Ltd(688315) relevant person in charge said that the increase in gross profit benefited from the increase in capacity utilization brought about by the growth of the company’s revenue scale on the one hand, and the improvement in efficiency brought about by the company’s intelligent production and information operation on the other hand.
Novogene Co.Ltd(688315) since its establishment, it has focused on providing gene technology services and firmly built infrastructure for industrial development. By the end of 2021, Novogene Co.Ltd(688315) has set up 5 experimental centers and 16 subsidiaries around the world; Its business scope covers about 70 countries and regions on six continents, serving more than 5900 customers in global research universities, scientific research institutes, hospitals, pharmaceutical R & D enterprises and agricultural enterprises.
The announcement shows that in order to achieve faster response and shorter delivery cycle, Novogene Co.Ltd(688315) started to strengthen the localization service capacity and started the preparations for new laboratories in Shanghai and other places during the reporting period. At the same time, Novogene Co.Ltd(688315) strengthen the construction of global logistics capacity to minimize the impact of repeated epidemics on Logistics timeliness.
Novogene Co.Ltd(688315) recently announced that it plans to issue shares to specific objects to raise funds, and further implement the strategy of “global localization” by building or expanding laboratories in Beijing, Tianjin, Shanghai, Guangzhou and other places, as well as Singapore, the United States, the United Kingdom and more countries and regions, so as to further deepen the company’s global layout on the existing basis.
In addition, Novogene Co.Ltd(688315) is constantly seeking breakthroughs in service quality. In February 2021, Novogene Co.Ltd(688315) UK Cambridge Experimental Center successfully passed the ISO / IEC 170252017 standard certification, and officially announced the launch of clinical sequencing services to provide European customers with gene sequencing solutions based on ngs services. Then, the British experimental center obtained the certification of good clinical laboratory practice (gclp), and its service ability was recognized internationally. In addition, Novogene Co.Ltd(688315) Tianjin experimental center and Singapore experimental center have completed the expansion of the third-generation sequencing platform, and officially became pacbio’s officially certified sequencing service provider in November, further improving their global third-generation sequencing service capacity and scale.
In terms of internal management, “intelligence” has always been the development keyword of Novogene Co.Ltd(688315) . In particular, since the launch of falcon, a flexible intelligent production line with multiple products in the ngs field in 2020, the delivery efficiency and quality of Novogene Co.Ltd(688315) have been significantly optimized. It is understood that Novogene Co.Ltd(688315) is developing a small intelligent production line Falcon II with lower cost and higher flexibility. It is planned to be officially released in 2022 and put into new and expanded global localization laboratories. Falcon broke the isolated island of collaboration in the sequencing process of ngs, and realized the intelligent operation of sample extraction, detection, database construction, library inspection, library pooling and biological information analysis. Compared with the super large falcon, Falcon II can be deployed to new and expanded laboratories more efficiently and conveniently, so as to realize the rapid improvement of production capacity and ensure the stable and efficient service quality to local customers.
